More positive data for Zolgensma in spinal muscular atrophy

Data published at a virtual Clinical Trial Session, conducted by the Muscular Dystrophy Association (MDA), show Zolgensma (onasemnogene abeparvovec-xioi) produced significant benefit to people with spinal muscular atrophy (SMA).

The data, which are drawn from a range of studies, are being presented virtually after the 2020 MDA Annual Conference was cancelled, due to the recent COVID-19 outbreak.

Novartis (NOVN: VX) company AveXis presented the data, which includes patients treated pre-symptomatically, and showed sustained durability in patients now up to five years post-dosing and some patients more than five years of age.